The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...

The company made another M&A play this month with its planned acquisition of spinal cord stimulation (SCS) company Nevro. “I’m proud of our team at Globus Medical, delivering incredible ...

95.5% of Nevro shares are held by institutional investors. 3.2% of Nevro shares are held by insiders. Comparatively, 17.4% of Adynxx shares are held by insiders. Strong institutional ownership is ...

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the transaction. Under the terms of the agreement, Globus Medical will pay ...

On February 7, 2025, Nevro Corp was acquired by Globus Medical (NYSE:GMED) in an all-cash transaction valuing NVRO at $5.85 per share, representing a total equity value of approximately $250 million.

Despite this strong quarter, Nevro's overall financial outlook remains challenging. The company maintained its 2024 sales guidance at $400-405 million, indicating a 5-6% year-over-year decline ...

On February 7, 2025, Nevro Corp was acquired by Globus Medical (NYSE:GMED) in an all-cash transaction valuing NVRO at $5.85 per share, representing a total equity value of approximately $250 million.